Amgen
Repatha
Biodrugs/ Drugs
Cardiovascular and circulatory systems
A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Impact of Evolocumab on Major Cardiovascular Events in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke
3Phase III in Spain,
2Phase II in Spain,
1Phase I in Spain